← Back to Clinical Trials
Recruiting NCT04632628

NCT04632628 Web-based Cognitive Behavioral Treatment for Insomnia in Dementia Caregivers

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04632628
Status Recruiting
Phase
Sponsor University of South Florida
Condition Insomnia Chronic
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2023-11-14
Primary Completion 2027-09-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Web-based Cognitive Behavior Therapy for Insomnia (CBT-I)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2023-11-14 with a primary completion date of 2027-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Over the next 30 years, more than 10 million persons living with dementia in the United States will receive care at home from an unpaid and untrained family caregiver. At home care is preferred by caregivers and persons with dementia alike, but increases the caregiver's risk of insomnia and related negative health outcomes, including depression, anxiety, cognitive disturbances and poor quality of life. Cognitive behavioral therapy for insomnia (CBT-I) is a highly effective and established evidence based treatment for adults of all ages. Although relatively understudied in dementia caregivers, the research by our group and others suggests CBT-I is also efficacious in caregivers. Our team developed a brief (4 session) CBT-I protocol specifically adapted for dementia caregivers (CBT-I) and has shown in person and remote (i.e. telehealth) delivery of this protocol significantly reduces insomnia symptoms and improves mood (moderate to large effects). Given demands on caregivers' time and limited availability of trained CBT-I providers, a web-based version of CBT-I (WebCBT-I; the online treatment will be called NiteCAPP) is needed to increase the accessibility of this efficacious treatment. WebCBT-I will allow for flexible at home scheduling, and the skills needed to monitor caregiver treatment progress can be quickly and efficiently taught to healthcare providers. The overarching goal of this project is to develop and test WebCBT-I in caregivers of persons with dementia. Objectives 1. To examine the clinical and health characteristics, including sleep, pain, fatigue, cognitive abilities, and cardiovascular health in dementia caregivers with insomnia. 2. To examine changes in the primary clinical outcomes, including complaints of poor sleep, and fatigue. 3. To examine changes in the secondary clinical outcomes, including mood, daytime functioning, cognitive functioning, and cardiovascular health. 4. To examine the mechanistic variables, including arousal (heart rate variability, HRV).

Eligibility Criteria

CAREGIVER Inclusion Criteria: * 18+ yrs * Dementia caregiver living with person with dementia * willing to be randomized, 4. read/understand English * insomnia diagnosis * no prescribed or over-the-counter sleep meds or stabilized 6+ weeks. Insomnia: * complaints for 6+ mos * adequate opportunity and circumstances for sleep * 1+ of the following: difficulty falling asleep, staying asleep, or waking too early * daytime dysfunction (mood, cognitive, social, occupational) due to insomnia * Screening interview indicates Insomnia Severity Index score ≥11 or Insomnia Severity Index score 9-10 * baseline diaries indicate \>30 mins of sleep onset latency or wake after sleep onset on 3+ nts. Exclusion Criteria: * unable to consent * cognitive impairment \[Telephone Interview for Cognitive Status (TICS) \<25 or Mini Mental State Examination (MMSE) \<26\] * sleep disorder other than insomnia \[i.e., sleep apnea (apnea/hypopnea index, AHI \>15)\] * bipolar or seizure disorder * other major psychopathology except depression or anxiety (e.g., suicidal ideation/intent, psychosis) * severe untreated psychiatric comorbidity * psychotropic or other medications (e.g., beta-blockers) that alter sleep * non-pharmacological tx for sleep or mood outside current trial. PERSONS WITH DEMENTIA Inclusion Criteria: * 18+ yrs * Persons with dementia living with caregiver * Have an eligible caregiver * willing to be randomized Exclusion Criteria: • Person with dementia or legally authorized representative is unable to consent

Contact & Investigator

Central Contact

Christina S McCrae

✉ mccraec@health.missouri.edu

📞 573-882-0982

Principal Investigator

Christina McCrae

PRINCIPAL INVESTIGATOR

University of Missouri-Columbia

Frequently Asked Questions

Who can join the NCT04632628 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Insomnia Chronic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04632628 currently recruiting?

Yes, NCT04632628 is actively recruiting participants. Contact the research team at mccraec@health.missouri.edu for enrollment information.

Where is the NCT04632628 trial being conducted?

This trial is being conducted at Columbia, United States.

Who is sponsoring the NCT04632628 clinical trial?

NCT04632628 is sponsored by University of South Florida. The principal investigator is Christina McCrae at University of Missouri-Columbia. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology